WO2009047280A3 - Polypeptidmarker zur diagnose von prostatakrebs - Google Patents

Polypeptidmarker zur diagnose von prostatakrebs Download PDF

Info

Publication number
WO2009047280A3
WO2009047280A3 PCT/EP2008/063499 EP2008063499W WO2009047280A3 WO 2009047280 A3 WO2009047280 A3 WO 2009047280A3 EP 2008063499 W EP2008063499 W EP 2008063499W WO 2009047280 A3 WO2009047280 A3 WO 2009047280A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
polypeptide marker
prostate cancer
polypeptide
marker
Prior art date
Application number
PCT/EP2008/063499
Other languages
English (en)
French (fr)
Other versions
WO2009047280A2 (de
Inventor
Harald Mischak
Original Assignee
Mosaiques Diagnostics & Therap
Harald Mischak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaiques Diagnostics & Therap, Harald Mischak filed Critical Mosaiques Diagnostics & Therap
Priority to AU2008309605A priority Critical patent/AU2008309605A1/en
Priority to CA2701571A priority patent/CA2701571A1/en
Priority to EP08837865A priority patent/EP2198305A2/de
Priority to US12/681,529 priority patent/US20100227411A1/en
Publication of WO2009047280A2 publication Critical patent/WO2009047280A2/de
Publication of WO2009047280A3 publication Critical patent/WO2009047280A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Verfahren zur Diagnose von Prostataerkrankungen umfassend den Schritt der Bestimmung einer Amplitude oder einer An- oder Abwesenheit mindestens eines Polypeptidmarkers in einer Probe, wobei der Polypeptidmarker ausgewählt ist aus den Markern 1 bis 141, die durch Werte für die Molekularmassen und die Migrationszeit charakterisiert sind.
PCT/EP2008/063499 2007-10-09 2008-10-09 Polypeptidmarker zur diagnose von prostatakrebs WO2009047280A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2008309605A AU2008309605A1 (en) 2007-10-09 2008-10-09 Polypeptide marker for the diagnosis of prostate cancer
CA2701571A CA2701571A1 (en) 2007-10-09 2008-10-09 Polypeptide markers for the diagnosis of prostate cancer
EP08837865A EP2198305A2 (de) 2007-10-09 2008-10-09 Polypeptidmarker zur diagnose von prostatakrebs
US12/681,529 US20100227411A1 (en) 2007-10-09 2008-10-09 Polypeptide markers for the diagnosis of prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118113.5 2007-10-09
EP07118113 2007-10-09

Publications (2)

Publication Number Publication Date
WO2009047280A2 WO2009047280A2 (de) 2009-04-16
WO2009047280A3 true WO2009047280A3 (de) 2009-06-18

Family

ID=38996900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/063499 WO2009047280A2 (de) 2007-10-09 2008-10-09 Polypeptidmarker zur diagnose von prostatakrebs

Country Status (5)

Country Link
US (1) US20100227411A1 (de)
EP (1) EP2198305A2 (de)
AU (1) AU2008309605A1 (de)
CA (1) CA2701571A1 (de)
WO (1) WO2009047280A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
ATE519116T1 (de) * 2007-03-07 2011-08-15 Mosaiques Diagnostics & Therap Verfahren zur normierung der konzentration von analyten in einer urinprobe
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
EP2255203A2 (de) * 2008-03-19 2010-12-01 Mosaiques Diagnostics And Therapeutics AG Verfahren und marker zur diagnose von tubulären nierenschäden und -erkrankungen
US20110214990A1 (en) * 2008-09-17 2011-09-08 Mosaiques Diagnostics And Therapeutics Ag Kidney cell carcinoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106129A2 (de) * 2005-04-07 2006-10-12 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnose von prostatakrebs
EP1757939A1 (de) * 2005-08-26 2007-02-28 mosaiques diagnostics and therapeutics AG Polypeptidmarker zur Diagnose von Blasenkrebs
WO2007063090A1 (de) * 2005-11-30 2007-06-07 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung der ureterabgangsstenose

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
WO2000037944A1 (en) * 1998-12-21 2000-06-29 Monash University Kidney disease detection and treatment
US6677114B1 (en) * 1999-04-20 2004-01-13 Target Discovery, Inc. Polypeptide fingerprinting methods and bioinformatics database system
DE10021737C2 (de) * 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
EP1301790B1 (de) * 2000-07-12 2008-04-09 Naser, Werner, Dr. Direkte bestimmung des quotients von analyt- zu referenzmolekülen
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
DE10304106A1 (de) * 2003-01-31 2004-08-26 Mosaiques Diagnostics And Therapeutics Ag Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
DE10341193A1 (de) * 2003-09-06 2005-03-31 Mosaiques Diagnostics And Therapeutics Ag Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen
US20050244973A1 (en) * 2004-04-29 2005-11-03 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
US20060024757A1 (en) * 2004-07-30 2006-02-02 Robert Hussa Detection of oncofetal fibronectin for selection of concepti
ATE519116T1 (de) * 2007-03-07 2011-08-15 Mosaiques Diagnostics & Therap Verfahren zur normierung der konzentration von analyten in einer urinprobe
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
EP2255203A2 (de) * 2008-03-19 2010-12-01 Mosaiques Diagnostics And Therapeutics AG Verfahren und marker zur diagnose von tubulären nierenschäden und -erkrankungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106129A2 (de) * 2005-04-07 2006-10-12 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnose von prostatakrebs
EP1757939A1 (de) * 2005-08-26 2007-02-28 mosaiques diagnostics and therapeutics AG Polypeptidmarker zur Diagnose von Blasenkrebs
WO2007063090A1 (de) * 2005-11-30 2007-06-07 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung der ureterabgangsstenose

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MISCHAK H ET AL: "Capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine", ANTICANCER RESEARCH, vol. 25, no. 6D, November 2005 (2005-11-01), & 13TH INTERNATIONAL HAMBURG SYMPOSIUM ON TUMOR MARKERS; HAMBURG, GERMANY; NOVEMBER 27 -29, 2005, pages 4793 - 4794, XP009095787, ISSN: 0250-7005 *
REHMAN I ET AL: "Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study", UROLOGY, BELLE MEAD, NJ, US, vol. 64, no. 6, December 2004 (2004-12-01), pages 1238 - 1243, XP002413220, ISSN: 0090-4295 *
See also references of EP2198305A2 *
THEODORESCU D ET AL: "PILOT STUDY OF CAPILLARY ELECTROPHORESIS COUPLED TO MASS SPECTROMETRY AS A TOOL TO DEFINE POTENTIAL PROSTATE CANCER BIOMARKERS IN URINE", ELECTROPHORESIS, WILEY-VCH VERLAG, WEINHEIM, DE, vol. 26, 2005, pages 2797 - 2808, XP000962767, ISSN: 0173-0835 *
THEODORESCU DAN ET AL: "Mass spectrometry based proteomics in urine biomarker discovery", WORLD JOURNAL OF UROLOGY, vol. 25, no. 5, 17 August 2007 (2007-08-17), pages 435 - 443, XP002468631, ISSN: 0724-4983 *

Also Published As

Publication number Publication date
EP2198305A2 (de) 2010-06-23
CA2701571A1 (en) 2009-04-16
US20100227411A1 (en) 2010-09-09
WO2009047280A2 (de) 2009-04-16
AU2008309605A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2007023191A3 (de) Polypeptidmarker zur diagnose von blasenkrebs
TWI317811B (de)
WO2009047280A3 (de) Polypeptidmarker zur diagnose von prostatakrebs
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2505668A3 (de) Verfahren auf Mikro-RNA-Basis zur Diagnose von Darm-, Lungen- und Bauchspeicheldrüsenkrebs
WO2004055519A3 (en) Specific markers for pancreatic cancer
WO2010009368A3 (en) Compositions for the detection and treatment of colorectal cancer
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
WO2003058201A3 (en) Methods for identifying marker genes for cancer
EP2021794B8 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
WO2005118879A3 (en) Identification of tumors
WO2011027310A8 (en) Novel tumor markers
WO2009115570A3 (de) Verfahren und marker zur diagnose von tubulären nierenschäden und -erkrankungen
WO2005111076A8 (en) Nectin 4 (n4) as a marker for cancer prognosis
WO2006092610A3 (en) Markers for melanoma
WO2007076174A3 (en) Methods, systems, and apparatus for multi-domain markers
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2011027308A8 (en) Novel tumor markers
WO2006106129A3 (de) Polypeptidmarker zur diagnose von prostatakrebs
WO2007082073A3 (en) Biomarkers for oral tongue cancer metastasis and extracapsular spread (ecs)
WO2011029954A3 (de) Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen
WO2009014565A3 (en) Methods for diagnosing and treating astrocytomas
WO2008108873A3 (en) Molecular biosensors for detecting macromolecules and other analytes
WO2008116178A8 (en) Systems and methods for diagnosis and prognosis of colorectal cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08837865

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008837865

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008309605

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2701571

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008309605

Country of ref document: AU

Date of ref document: 20081009

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12681529

Country of ref document: US